5:56 PM
 | 
May 15, 2013
 |  BC Extra  |  Company News

FDA approves radium-223 from Bayer, Algeta

FDA approved an NDA from Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is indicated for men...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >